JP Morgan Chase’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,869,728
| Closed | -$152M | – | 8076 |
|
|
2026
Q1 | $152M | Buy |
2,869,728
+1,096,702
| +62% | +$45M | 0.01% | 803 |
|
|
2025
Q4 | $71.6M | Buy |
1,773,026
+1,090,318
| +160% | +$25.2M | ﹤0.01% | 1130 |
|
|
2025
Q3 | $5.13M | Buy |
682,708
+324,502
| +91% | +$2.07M | ﹤0.01% | 3339 |
|
|
2025
Q2 | $1.34M | Buy |
358,206
+64,011
| +22% | +$200K | ﹤0.01% | 4205 |
|
|
2025
Q1 | $812K | Buy |
294,195
+242,365
| +468% | +$990K | ﹤0.01% | 4481 |
|
|
2024
Q4 | $287K | Sell |
51,830
-7,706
| -13% | -$52.2K | ﹤0.01% | 5318 |
|
|
2024
Q3 | $497K | Sell |
59,536
-93,544
| -61% | -$770K | ﹤0.01% | 4894 |
|
|
2024
Q2 | $1.04M | Sell |
153,080
-268,557
| -64% | -$1.63M | ﹤0.01% | 4247 |
|
|
2024
Q1 | $2.77M | Buy |
421,637
+203,436
| +93% | +$1.33M | ﹤0.01% | 3583 |
|
|
2023
Q4 | $1.42M | Sell |
218,201
-64,934
| -23% | -$343K | ﹤0.01% | 4093 |
|
|
2023
Q3 | $1.42M | Sell |
283,135
-98,480
| -26% | -$625K | ﹤0.01% | 3812 |
|
|
2023
Q2 | $3.34M | Sell |
381,615
-250,131
| -40% | -$2.92M | ﹤0.01% | 3167 |
|
|
2023
Q1 | $7.48M | Sell |
631,746
-575,405
| -48% | -$5.5M | ﹤0.01% | 2520 |
|
|
2022
Q4 | $12.3M | Buy |
1,207,151
+288,109
| +31% | +$1.92M | ﹤0.01% | 2065 |
|
|
2022
Q3 | $5.41M | Buy |
919,042
+918,079
| +95,335% | +$3.41M | ﹤0.01% | 2673 |
|
|
2022
Q2 | $2K | Sell |
963
-8,404
| -90% | -$16.8K | ﹤0.01% | 6302 |
|
|
2022
Q1 | $28K | Buy |
9,367
+1,923
| +26% | +$8.21K | ﹤0.01% | 5999 |
|
|
2021
Q4 | $52K | Buy |
7,444
+2,190
| +42% | +$18.2K | ﹤0.01% | 5932 |
|
|
2021
Q3 | $55K | Sell |
5,254
-6,165
| -54% | -$64K | ﹤0.01% | 5813 |
|
|
2021
Q2 | $140K | Sell |
11,419
-12,117
| -51% | -$206K | ﹤0.01% | 5415 |
|
|
2021
Q1 | $518K | Buy |
+23,536
| New | +$516K | ﹤0.01% | 4657 |
|
Other funds holding TERN
JP Morgan Chase's TERN Position: Q2 2026 in Review
JP Morgan Chase sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,869,728 shares — an estimated $152M sold.
JP Morgan Chase first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $152M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- JP Morgan Chase reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 2,869,728 Terns Pharmaceuticals shares in Q2 2026, an estimated $152M.
- JP Morgan Chase first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- JP Morgan Chase's Terns Pharmaceuticals position peaked at $152M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.